chr11-47337420-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM1PP3_Moderate
The NM_000256.3(MYBPC3):c.2573G>A(p.Ser858Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000112 in 1,603,490 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.2573G>A | p.Ser858Asn | missense_variant | 25/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.2573G>A | p.Ser858Asn | missense_variant | 25/35 | 5 | NM_000256.3 | ENSP00000442795 | P4 | |
MYBPC3 | ENST00000399249.6 | c.2573G>A | p.Ser858Asn | missense_variant | 24/34 | 5 | ENSP00000382193 | A2 | ||
MYBPC3 | ENST00000544791.1 | c.*78G>A | 3_prime_UTR_variant, NMD_transcript_variant | 25/27 | 5 | ENSP00000444259 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152190Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000413 AC: 1AN: 242216Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 131522
GnomAD4 exome AF: 0.0000110 AC: 16AN: 1451300Hom.: 0 Cov.: 33 AF XY: 0.0000111 AC XY: 8AN XY: 720608
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152190Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74348
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 20, 2020 | The p.Ser858Asn variant in MYPBC3 has been identified in at least 12 individuals with HCM and segregated with disease in 1 affected family member (Walsh 2017 PMID: 27532257, Ambry pers. comm., GeneDx pers. comm., Invitae pers. comm., LMM data). Additionally, it was identified in several individuals, some with earlier onset or more severe presentations, who carried additional pathogenic variants in other cardiomyopathy related genes (Ambry pers. Comm., Invitae pers. Comm., GeneDx pers. comm.). This variant has also been reported in ClinVar (Variation ID # 164070) and has been identified in 2/124800 of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant HCM. ACMG/AMP criteria applied: PS4, PM2_Supporting, PP3. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 858 of the MYBPC3 protein (p.Ser858Asn). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 20378854, 27532257, 31006259). ClinVar contains an entry for this variant (Variation ID: 164070). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Apr 12, 2019 | The c.2573G>A p.Ser858Asn variant (rs727503185) has been reported in at least 6 individuals with hypertrophic cardiomyopathy (Morita. 2008, and Walsh 2017). However, in at least one individual the p.Ser858Asn variant was identified with another pathogenic variant of MYBPC3 and family segregation data of the p.Ser858Asn variant was not readily available for any of the individuals. This variant is reported as a variant of uncertain significance by 5 laboratories in ClinVar (Variation ID: 164070). This variant is only observed on two alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The serine at codon 858 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Due to limited information, the clinical significance of the p.Ser858Asn variant is uncertain at this time. - |
Uncertain significance, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Nov 20, 2014 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p.Ser858Asn (c.2573G>A). in MYBPC3 Given the lack of case data, we consider this variant a variant of uncertain significance and we do not feel it is suitable for assessing risk in healthy relatives ("predictive genetic testing"). Per ClinVar, LMM also classifies it as a variant of uncertain significance (last reviewed by them in 2010, evidence and internal data not provided). The variant has been seen in at least one case of HCM (not including this patient's family), though that patient carried another pathogenic variant. Morita et al (2008) reported the presence of this variant in one individual with HCM. This patient was diagnosed early in childhood and also carried an additional variant in the MYBPC3 gene which is very likely disease causing and is actually the most common HCM-causing variant, present in 2.4% of patients with HCM (p.Arg502Trp). The authors did not report data on segregation or phasing. This is likely the same case that was reported by Saltzman et al (2010). Serine is highly conserved across species at position 858 in MYBPC3 gene. The amino acid change is chemically conservative, with a polar, neutral Serine being replaced by a polar, neutral Asparagine. Three is no variation at codon 858 listed in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/), which currently includes variant calls on ~64,000 individuals of European, African, Latino and Asian descent (as of August 27th, 2015). There is adequate coverage.This variant was not identified in 680 presumed healthy controls (Morita et al 2008). - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 13, 2022 | Reported in association with cardiomyopathy; however, at least one family harbored an additional pathogenic variant in the MYBPC3 gene (Morita et al., 2008; Saltzman et al., 2010; Ho et al., 2013; Walsh et al., 2017); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23549607, 20378854, 18403758, 18761664, 27532257, 25228707, 31006259) - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 18, 2023 | The p.S858N variant (also known as c.2573G>A), located in coding exon 25 of the MYBPC3 gene, results from a G to A substitution at nucleotide position 2573. The serine at codon 858 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been reported in patients with hypertrophic cardiomyopathy (HCM) and HCM genetic testing cohorts; however, other variants in cardiomyopathy-associated genes were detected in some cases and/or clinical detail was limited (Morita H et al. N. Engl. J. Med. 2008;358:1899-908; Walsh R et al. Genet. Med. 2017;19:192-203; Norrish G et al. Circulation. 2019 Jul;140(3):184-192; Field E et al. J Med Genet. 2022 Aug;59(8):768-775). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at